Cargando…
Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes
Objective. Anakinra is approved for the treatment of RA and cryopyrin-associated periodic syndromes (CAPS). While the anakinra safety profile is well established in RA, the long-term safety profile in severe CAPS is less well documented and will therefore be discussed in this report. Methods. A pros...
Autores principales: | Kullenberg, Torbjörn, Löfqvist, Malin, Leinonen, Mika, Goldbach-Mansky, Raphaela, Olivecrona, Hans |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957676/ https://www.ncbi.nlm.nih.gov/pubmed/27143789 http://dx.doi.org/10.1093/rheumatology/kew208 |
Ejemplares similares
-
The IL-1 receptor antagonist anakinra (kineret®) stabilizes the NLRP3 mutation-specific risk for hearing loss in patients with severe cryopyrin-associated periodic syndromes (CAPS)
por: Leinonen, Mika, et al.
Publicado: (2014) -
PReS-FINAL-2326: No correlation between anti-drug antibodies and pharmacokinetics, efficacy or safety of Anakinra (Kineret(®)) in patients with severe CAPS
por: Wikén, M, et al.
Publicado: (2013) -
Anakinra and related drugs targeting interleukin-1 in the treatment of cryopyrin-associated periodic syndromes
por: Bachove, Inessa, et al.
Publicado: (2014) -
A Retrospective Patient Chart Review and Survey in Patients with Cryopyrin-associated Periodic Syndromes Treated with Anakinra
por: Lachmann, Helen J., et al.
Publicado: (2013) -
PW02-039 - Long-term anakinra treatment in CAPS: a metaanalys
por: Leinonen, M, et al.
Publicado: (2013)